We chose CA125 as a surrogate marker for Cluster 13 in a larger bladder cancer cohort (14 HV tumors, 20 UC tumors) due to its extensive history as a tumor marker in other cancers and the availability of clinically validated antibodies. This evidence concerns the gene MUC16 and urinary bladder cancer.